Global Migraine Market Spotlight 2017-2027: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, and Patent Information
DUBLIN, Jan. 11, 2018 /PRNewswire/ --
The "Market Spotlight: Migraine" report has been added to Research and Markets' offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This Market Spotlight report covers the Migraine market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
-- The author estimates that in 2016, there were 569.8 million prevalent
cases of migraine in adults aged 20 years and older worldwide, and
forecasts that number to increase to 638.4 million prevalent cases by
2025.
-- Latin America and the Caribbean is estimated to have the highest disease
prevalence (16.40%), while Northern America has the lowest prevalence
(9.70%).
-- A large number of industry-sponsored drugs in active clinical
development for migraine are in Phase III. Mid- and late-stage drugs in
development for migraine are predominantly focusing on targets such as
the serotonin 5-HT1 receptor, CGRP receptor, and nitric oxide synthase.
Among these classes, the CGRP antagonists hold considerable promise
owing to their specific targeting of migraine mechanisms, contrary to
conventional treatments, and prophylactic efficacy. In particular,
Aimovig is the most clinically advanced monoclonal antibody against
CGRP, and has been demonstrated to significantly reduce the number of
migraine days per month in episodic migraine patients. Approximately
half of the drugs in mid- to late-stage development for migraine are
administered via the oral route, with the remainder being intranasal,
inhaled, subcutaneous, intravenous, and intramuscular formulations.
-- The majority of approved drugs in the migraine space target serotonin
5-HT1 receptors or GABA receptors. These are commonly administered via
the oral route, with a few select products being available in
intranasal, intramuscular, and subcutaneous formulations.
-- High-impact upcoming events for drugs in the migraine space include
topline Phase II and Phase III trial results, as well as FDA decisions
on BLAs.
-- Licensing and asset acquisition activity involving migraine drugs has
been weak during 2012-17, although 2016 witnessed the highest number of
licensing deals during this period. The exclusive agreement between
Bristol-Myers Squibb and Biohaven in 2016 to develop and commercialize
rimegepant and BHV-3500, as well as rights to other CGRP-related
intellectual property for $523.5m, was the largest deal during 2012-17.
-- During 2017-21, formulation patent expiries of Depakote (2019) and Zomig
(2021), and device patent expiry of Onzetra (2020) are expected to open
the door to generic entry.
-- Botox's sales during 2012-16 were the highest of any approved migraine
drug, and are forecast to grow through 2022, reaching $4.4bn in 2022.
However, only a portion of Botox's revenues derive from its therapeutic
use in migraine prophylaxis.
-- The number of clinical trials at each of Phase I-IV indicates an even
distribution of trials across the phases. The US has a substantial lead
in the number of migraine clinical trials globally, yet forecasted
prevalent cases of migraine are lower in North America as compared to
Asia and Europe. Germany leads the major EU markets, while Asia is
forecasted to have the largest number of prevalent cases of migraine.
-- Relatively few clinical trials are ongoing, compared to the vast body of
evidence among completed studies. GlaxoSmithKline has the highest number
of completed migraine trials, while Eli Lilly has the most ongoing
trials. Pharma giants are the main sponsors of migraine clinical trials,
such as GlaxoSmithKline, Merck & Co, Allergan, Eli Lilly, Johnson &
Johnson, Pfizer, and Teva.
-- Many of the main industry sponsors have more Phase III trials than any
other stage. GlaxoSmithKline, Merck & Co, and Johnson & Johnson in
particular appear to be top-heavy, with most of their trials in Phase
III-IV.
Key Topics Covered:
1 KEY TAKEAWAYS
2 DISEASE BACKGROUND
-- Disease subtypes
3 TREATMENT
-- Analgesics
4 NSAIDs
-- Serotonergic drugs
-- Prophylactic agents for migraine
5 EPIDEMIOLOGY
6 PIPELINE DRUGS
7 MARKETED DRUGS
-- Approvals by country
8 KEY UPCOMING EVENTS
9 LICENSING AND ASSET ACQUISITION DEALS
-- Eli Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For
$1m
-- AstraZeneca Divests Zomig To Grunenthal
10 PARENT PATENTS
11 REVENUE OPPORTUNITY
12 CLINICAL TRIAL LANDSCAPE
-- Sponsors by status
-- Sponsors by phase
-- Recent events
13 BIBLIOGRAPHY
-- Prescription information
14 APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/8nb85v/global_migraine?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
